key: cord-0731361-agm6xi21
authors: Yang, Shuyi; Shi, Yuxin; Lu, Hongzhou; Xu, Jianqing; Li, Feng; Qian, Zhiping; Hua, Xinyan; Ding, Xueting; Song, Fengxiang; Shen, Jie; Lu, Yang; Shan, Fei; Zhang, Zhiyong
title: Clinical and CT features of early-stage patients with COVID-19: a retrospective analysis of imported cases in Shanghai, China
date: 2020-03-26
journal: Eur Respir J
DOI: 10.1183/13993003.00407-2020
sha: 8ff614d336b8be34c4afde0226d9de73e0f0711c
doc_id: 731361
cord_uid: agm6xi21

Since December 2019, some patients with novel corona virus infectious disease (COVID-19) emerged in Wuhan, Hubei, China [1]. The pathogen analysis discovered a new type of coronavirus from infected airway epithelial cells [2] and named as sever acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) [3]. At the time of Chinese people were heading home for celebrating the Spring Festival, many latent cases left Wuhan, which led to the emergence of imported COVID-19 cases across the mainland of China and some other countries [4, 5]. Shanghai is one of the major cities with imported cases [4, 5].

Since December 2019, some patients with novel corona virus infectious disease emerged in Wuhan, Hubei, China [1] . The pathogen analysis discovered a new type of coronavirus from infected airway epithelial cells [2] and named as sever acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) [3] . At the time of Chinese people were heading home for celebrating the Spring Festival, many latent cases left Wuhan, which led to the emergence of imported COVID-19 cases across the mainland of China and some other countries [4] [5] . Shanghai is one of the major cities with imported cases [4] [5] .

COVID-19 are diagnosed mainly by real-time PCR (RT-PCR) to detect SARS-CoV-2 nucleic acid [4] . Due to the limited supply of RT-PCR kit and false-negative nucleic acid cases emerged, some experts have proposed to diagnose suspected cases using the time-saving chest computed tomography (CT) rather than RT-PCR [6] . CT features at the early-stage of COVID-19 have not particularly studied yet, which is vital to the early identification of suspected cases. The purpose of this study was to explore the early-stage clinical and CT features of nucleic acid-positive COVID-19.

From January 20 to 30, 2020, forty-four COVID-19 patients (male: female, 25:19; median age, 48.5 years; age range, 20-76 years) in our institution who met the entry criteria (patients' interval time between onset symptom and CT scan was less than 4 days [7] ), were enrolled in this study. Their clinical data included the onset symptoms and main laboratory findings (divided into 3 groups; A, decreased; B, normal; C, elevated). Observation parameters on CT included lesions distribution, size (maximum diameter in axial images), attenuation category (type I, pure ground-glass opacities-pGGOs; type II, GGOs with consolidation; type III, GGOs with interlobular septal thickening; type IV, consolidation), lesion-related signs (vessel expansion, air bronchogram), mediastinal lymphadenectasis (>1 cm in short-axis diameter) and pleural effusion.

CT score was defined to quantify the pulmonary lesions in CT. The design formula was "size (cm) * attenuation category weight". The attenuation category weight was "1" for type I, "2" for type II/III, and "3" for type IV, which was discussed by two experienced chest radiologists, especially for the infectious disease diagnosis.

Of all the 44 patients, the onset symptoms were mainly fever (95.45%), followed by fatigue posterior part (71.71%, type I: 51.17%) of the lung. The size of type I was 1.37±1.08 cm (range, 0.34-8.53 cm), significantly smaller than that of type II (2.12 ± 2.00 cm, 0.3-13.53 cm, P < 0.001), but no statistically difference with type IV (1.52 ± 0.88 cm, 0.38-3.12cm, P = 0.2553). The size of type II was significantly smaller than that of type III (4.7 ± 2.58 cm, 1.36-11.90 cm, P < 0.001), but no statistically difference with type IV (P = 0.4632). The size of type III was also significantly larger than that of type IV (P < 0.001). The CT score was 38.44 ± 34.56 (range, 0-136. 13 In our study, most patients' onset symptoms were fever, which was similar to SARS-CoV [8] and MERS-CoV [9] , but the other symptoms of COVID-19 is mild. 52.27% patients' lymphocytes count decreased which is valuable to the early diagnosis. Some experts suggested that COVID-19 might mainly act on lymphocytes, especially T lymphocytes, as does SARS-CoV [10] . Many patients' CD3 + T, CD4 + T, and CD8 + T cell counts also decreased which indicated COVID-19 could attack immunocyte and lead to the imbalanced immune regulation. The CD4 + T cell counts, as well as CRP and LDH got linear regression to the severity of pulmonary lesions on CT, which was not depicted before. Significantly, those indicators enrolled in the model were the first value and divided as the category variable, which might indicate the patients' onset pulmonary severity levels. Similar to MERS-CoV or SARS-CoV infection [9] , some patients presented elevated level of liver aminotransferase, which may indicate the potential liver injury [11] .

13.64% patients' pulmonary lesions are mild in the early stage, which are easy to be misdiagnosed. All the lesions of COVID-19 have a predominant distribution in the peripheral part of the lung (92.11%). Pulmonary lesions, except type I, have a predominant distribution in the posterior part of the lung, which is vital to the early diagnosis and had not depicted previously. In the early stage of COVID-19, most pulmonary lesions represent as type II, followed by type I, while type III and type IV are rare. The size of lesion represents as type IV is small, nearly to type I and II, in contrast to the advanced COVID-19 which may show wide consolidation [7] . The consolidation is also common in H7N9 pneumonia [12] , bacterial pneumonia, invasive fungal disease [13] and some other virus pneumonia [14] . 81.82% patients' follow-up CT showed disease progression, which is in accordance with the time course of lung changes that the greatest severity approximately 10 days after onset symptoms [15] .

In conclusion, fever is the main onset symptom of COVID-19. Decreased lymphocyte count is an important indicator for diagnosis. The features of early-stage COVID-19 include GGOs-based lesions with rare small size consolidation mainly distributed in the peripheral and posterior part of the lung. Some patients' pulmonary lesions are small and focal, which should capture physicians' attention. The level of decreased CD4 + T cell, elevated CRP and LDH may prompt the severity of CT imaging.

Director-General's remarks at the media briefing on 2019-nCoV on 11

A new coronavirus associated with human respiratory disease in China

Severe acute respiratory syndrome-related coronavirus -The species and its viruses, a statement of the Coronavirus Study Group

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

COVID-19) situation report -33

Virus-hit Wuhan speeds up diagnosis of patients

Emerging Coronavirus 2019-nCoV Pneumonia

SARS: clinical features and diagnosis

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection

Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings

Pulmonary invasive fungal disease and bacterial pneumonia: a comparative study with high-resolution CT

Radiographic and CT features of viral pneumonia

Figure Figure: A 64 years old female, the first CT shows lesions manifested as type II and III with pleural thickening and adhesion

Seven days follow-up CT shows lesions size broaden, and density increased, which means progression (D)

We express our sincere wishes and greatest respects to the front-line workers, who are fighting against the COVID-19.